Optimal'nyy rezhim lecheniya posttsitostaticheskoy anemii s pomoshch'yu Epreksa


Дәйексөз келтіру

Толық мәтін

Аннотация

Среди осложнений противоопухолевого лечения постцитостатическая анемия (ПЦА) является главной причиной ухудшения качества жизни больных. Обсуждается проблема выбора оптимального режима лечения ПЦА. Признанными методами коррекции ПЦА считаются курсовое лечение эритопоэзстимулирующими препаратами (эпоэтином альфа, эпоэтином бета, дарбэпоэтином альфа) и/или периодические трансфузии эритроцитарной массы. Приводятся результаты фармакокинетических исследований, подтверждающих целесообразность однократного еженедельного введения Эпрекса (эпоэтина альфа) в дозе 40 тыс. МЕ как эффективного, надежного и предсказуемого метода коррекции анемии у онкологических больных. Помимо клинической эффективности лекарственного средства в практической онкологии учитывают удобство применения препарата и стоимость курса лечения. Сравнительный фармакоэкономический анализ (стоимость-польза) позволяет выделить еженедельный режим лечения ПЦА как наименее затратный среди прочих.

Толық мәтін

Рұқсат жабық

Авторлар туралы

V. Breder

Әдебиет тізімі

  1. Cella D. The effect of anemia and anemia treatment on the quality of life of people with cancer. Oncology 2002;16(Suppl. 10):125-32.
  2. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999;91:1616-34.
  3. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): the first large, multinational, prospective survey defining the prevalence, incidence, and treatment of anemia in cancer patients. Eur J Cancer 2004;40:2293-307.
  4. Matsumoto T, Endoh K, Kamisango K, et al. Effect of recombinant human erythropoietin on anticancer drug-induced anaemia. Br J Haematol 1990;75(4):463-68.
  5. Wood PA, Hrushesky WJ. Cisplatin-associated anemia: an erythropoietin deficiency syndrome J Clin Invest 1995;95(4):1650-59.
  6. Barrett-Lee PJ, Ludwig H, Birgegard G, et al. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey. Oncology 2006;70(1):34-48.
  7. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001;84(Suppl. 1):3-10.
  8. Jamal NM. Evaluation of Epoetin Alpha (rHu-EPO) and Darbepoietin Alpha on Burst-colony formation (BFU-E) in culture. J Int Medical Res 2006;34:42-51.
  9. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392-950.
  10. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update. J Clin Oncol 2008;1:13249.
  11. Abels RI. Recombinant human erythropoietin in the treatment. of the anaemia of cancer. Acta Haematol 1992;87:4-11.
  12. Krantz SB. Blood 1991;77:419-34.
  13. Miller C, Jones R, Piantadosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689-92.
  14. Littlewood TJ, Bajetta E, Nortier JWR, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74.
  15. Cheung WK, Goon BL, Guilfoyle MC, et al. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther 1998;64:412-23.
  16. Cheung W, Minton N, Gunawardena K. Phar macokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 2001;57:411-18.
  17. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-82.
  18. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of Epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005; 23 (12):2606-617.
  19. Zagari M. An open label, controlled, randomized, dose comparison study of epoetin alfa for the treatment of anemia in cancer patients receiving platinum containing chemotherapy European Hematology Association 2003 poster.
  20. Cazzola M, et al. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003;122:386-93.
  21. Gascon P, et al. Ann Oncol 2006;17:1019P.
  22. Pirker R, et al. A phase 3, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum treatment for lung cancer. 37th Ann Meet Proc of ASCO 2001;20(pt 1): abstr. 1572.
  23. Vansteenkiste J, Pirker R, Massuti B, et al. for the Aranesp™ 980297 Study Group. Double blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94: 1211-20.
  24. Waltzman RJ, Croot C, Justice GR, et al. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 mcg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 2006;10:642-50.
  25. Schwartzberg LS, Yee LK, Senecal FM, et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 2004;9:696-707.
  26. Cremieux P, Vekeman F, Lefebvre P. Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: a Canadian application. J Oncol Pharm Pract 2006;12:165.
  27. Scott S. Dose conversion from recombinant human erythropoietin to darbepoetin alfa. Pharmacotherapy 2002;22:160S-65S.
  28. Rosberg JH, Ben-Hamadi R, Cremieux PY, et al. Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anaemia. Clin Drug Invest 2005;25:33-48.
  29. Macdougall IC, Eckardt K-U. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 2006;368:947-53.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2008

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>